Celltrion Eyes Direct Global Sales To Bolster Margins, Growth
Executive Summary
Biosimilar specialist Celltrion is aiming for the next stage of growth by setting up its own global direct sales and marketing system and through a new subcutaneous formulation of infliximab, and is looking to begin discussions with existing overseas marketing partners.
You may also be interested in...
Celltrion Will Sell World's First Subcutaneous Infliximab Directly In Europe
Celltrion has set out plans to market directly its subcutaneous version of infliximab in Europe. The firm has just received a nod that sets the stage for approval across the EU, albeit with more limited indications than the existing intravenous version.
Celltrion Will Market Subcutaneous Remsima Directly After EU Nod
Celltrion has set out plans to market directly its subcutaneous version of infliximab in Europe. The firm has just received a nod that sets the stage for approval across the EU, albeit with more limited indications than the existing intravenous version.
Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys
Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.